Medical treatment appears to be an effective and safe way to normalize cortisol levels in patients with Cushing’s syndrome, and may be a treatment option, a review study reports. The research, “Effectiveness of medical treatment for Cushing’s syndrome: a systematic review and meta-analysis,” appeared in the…
News
Children with pituitary adenomas have similar responses to surgery and long-term outcomes as adult patients with the same type of tumors, new research shows. The only exception are growth hormone (GH)-secreting tumors, which have higher recurrence rates in children than adults. The study, “Pediatric Pituitary Adenomas: Early and…
Researchers have identified several parameters that could help distinguish silent corticotroph adenomas — benign pituitary tumors that produce adrenocorticotropic hormone — from other nonfunctioning pituitary tumors. Because these tumors usually have a more aggressive clinical course, the findings may help determine the most appropriate management approach for patients before they undergo…
As President Trump signed the recently passed Right to Try legislation into law in a White House ceremony, Jordan McLinn of Indianapolis tried twice to embrace him. The third time, 9-year-old Jordan finally got the hug he wanted — as well as a kiss on the forehead. The video of…
A noninvasive and inexpensive technique could help improve the clinical assessment of bone damage in Cushing’s syndrome patients, a French study reports. The approach, called trabecular bone score, was better at detecting bone damage in these patients than the standard bone mineral density assessments. The study, “Assessment…
Finding treatments and potential cures for rare diseases is crucial, but so is the quality of patients’ lives — a rather nebulous term that means different things to different people. “Recently, there’s been much more of a focus on Quality of Life (QoL) issues, real-world evidence and patient-reported outcomes,” said…
Signifor LAR Shows Long-term Benefits for Cushing’s Disease Patients in Phase 3 Extension Trial
Long-term treatment with Signifor LAR, a long-acting formulation of pasireotide, effectively reduced pituitary tumor volume and improved symptoms of Cushing’s disease, results from a Phase 3 extension trial show. These findings were discussed in the poster, “Long-Term Efficacy and Safety of Once-Monthly Pasireotide in Patients…
Radiation to the Whole Pituitary Compartment Effective at Controlling Cushing’s, Study Contends
Radiation therapy targeting the entire sella — the compartment where the pituitary gland resides at the base of the brain — is effective at controlling Cushing’s disease and should be considered for patients with suspected invasive adenoma tumors, a new study shows. The study, “Technique of Whole-Sellar Stereotactic Radiosurgery for…
Cushing’s disease patients with macroadenomas — pituitary tumors larger than 10 mm — should undergo transsphenoidal pituitary surgery using the endoscopic technique, according to a new systematic review. The study, “Endoscopic vs. microscopic transsphenoidal surgery for Cushing’s disease: a systematic review and meta-analysis,” was published in…
Heart problems in Cushing’s syndrome patients may be partially reversed after tumor removal surgery, new research shows. For most patients in the study, the surgery also improved quality of life, mental and physical health, anxiety, and depression. However, 1 in 3 patients showed worse anxiety and depression scores, researchers…
Recent Posts
- Sonic Hedgehog pathway may be target in Cushing’s disease
- Incidental adrenal mass leads to man’s Cushing’s diagnosis: Report
- What a Cushing’s disease flare-up looks like for me
- Rare case study details double Cushing’s syndrome/disease diagnosis
- Quality of life improvements vary widely after Cushing’s disease surgery
- How I explain Cushing’s disease to children
- Asedebart for Cushing’s disease granted orphan drug status in Japan
- Father, daughter with Cushing’s disease share CDKN1B variant
- How does Cushing’s disease affect the menstrual cycle?
- Abnormal blood proteins in remission suggest lasting Cushing’s risks